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ABSTRACT
Infectious diseases remain a serious and now re-emerging threat to human life, contributing to over ten
million deaths per year. Treatment of major infectious diseases with antibacterial agents creates an
ongoing and escalating public health issue that currently leads to more problems than solutions. By
processes of adaptation and survival, bacteria consistently develop mechanisms to overcome the effects
of the newest and most potent antibacterial compounds. Simultaneously, progressively fewer
antibacterial agents are being developed by pharmaceutical and biotechnology companies. Although
this dilemma is an inherent trade-off and has no imminent resolution, the most prudent paradigm to
pursue is the judicious use of antibacterial agents in the most limited way possible to attain the desired
treatment results. One straightforward approach to antimicrobial stewardship is to use a single agent as
opposed to combination therapy, so as to subject bacteria to lower total antibiotic exposure whenever
feasible. This article reviews current trends in antibacterial drug development and describes a context
for adherence to monotherapy with newer agents.
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INTRODUCTION
A potential ‘post-antibiotic era’ is threatening
present and future medical advances. According
to the WHO, there is a global risk of creating an
environment similar to that of the pre-antibiotic
era (i.e. before the middle of the 20th century),
when deaths from infectious diseases were much
more prevalent than they are currently, and
modern implant and transplant surgery was
impossible because of the risk of infection. Emer-
gence of antimicrobial resistance is a natural
phenomenon that is caused largely by antimicro-
bial use (and misuse). There is a global pandemic
of resistant organisms that requires changes in
how we address the problem [1]. In parallel with
escalating resistance, the rate of development of
new antimicrobial agents is declining, while rates
of morbidity and mortality, and the costs associ-
ated with suboptimal treatment of infections
caused by resistant organisms, are rising [2]. The
combination of the current worldwide increase in
resistant bacteria and the downward trend in the
development of new antibiotics has serious health
and economic implications [3–5]. Resistant bacte-
ria dramatically reduce the possibility of treating
infectious diseases effectively, increasing the risk
of complications and fatal outcomes.
Indeed, the pipelines of the world’s 15 largest
pharmaceutical companies reﬂect a notable de-
cline in the number of new antimicrobial agents
under development and recently introduced. A
survey by Spellberg et al. found that nine new
antibacterial agents were introduced between
1998 and 2003, a drop from 16 such agents
introduced between 1983 and 1987 (the ﬁrst
period for which the authors obtained data), with
a steady decline during the intervening years up
to the present [5]. Tigecycline, the ﬁrst of the
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glycylcyclines, a new class of semisynthetic tetra-
cyclines, was introduced in 2005, giving a current
total of ten new antibacterials in the last decade;
most, tigecycline included, represent extensions
of an existing class of compounds. The authors
contrasted this with the current trend in the
number of new molecular entities (NMEs) in
other drug classes being developed by the same
companies, citing public disclosures of 23 NMEs
for depression and anxiety, eight for bladder
hyperactivity, and seven for osteoporosis, in
contrast to only ﬁve antibacterial NMEs. Simi-
larly, the world’s seven largest biotechnology
companies reported having a total 52 NMEs in
development for indications in the areas of
oncology, inﬂammation ⁄ immunomodulation and
metabolism ⁄ endocrinology, but only one for anti-
bacterial therapy [5]. The challenge of new anti-
microbial development is one of the issues
addressed by the recent Infectious Diseases Soci-
ety of America (IDSA) policy document on anti-
biotic resistance [1].
As few new antibacterials are being developed,
the global need for a cooperative effort to ensure
their appropriate use is increasing, with the
objective of reducing the emergence of resistance.
There is a need in the drug development process
for a comprehensive approach that works in
concert with health, education, economic and
industrial policies. Containment of antibiotic
resistance will depend on coordinated interven-
tions to optimize antibiotic consumption. The
current rising trends in resistance to antimicrobial
agents suggest that the real problems are still
ahead of us [2].
In the interim, judicious use of existing anti-
bacterials is paramount, but how to achieve this
practically is unclear. It is realistic to hypothesize
that the fewer antibacterials used the better, with
less exposure to antimicrobials limiting the
opportunity for microbes to develop resistance
to these critical agents. Put another way, the fewer
antibacterials used, the less the selection pressure
on organisms that might develop resistance to
multiple agents when used together. However,
the use of fewer antimicrobial agents is not
acceptable if it is accompanied by worse thera-
peutic outcomes.
Conceptually, the efﬁcacy of monotherapy
must be proven, as was done by a meta-analysis
of randomized, controlled studies in a report by
Bliziotis et al. [6]. They showed that rates of
treatment failure attributable to the emergence
of resistance, the development of superinfection
or overall disease mortality did not differ signi-
ﬁcantly between b-lactam monotherapy and com-
bination regimens containing a b-lactam and an
aminoglycoside. Although generalization is prob-
ably unwise, the concept of monotherapy could
become one practical pillar of antimicrobial stew-
ardship, involving only one antimicrobial agent
whenever possible while still covering the
breadth of likely infecting pathogens.
The goals of this article are to: (i) discuss the
antibiotics currently available for initial therapy;
(ii) summarize the mechanisms of resistance to
antimicrobials; and (iii) describe the microbiolog-
ical and clinical proﬁle of tigecycline, the ﬁrst in a
new group of broad-spectrum agents, the gly-
cylcyclines, which provides a new, practical
opportunity for increased use of monotherapy in
the seriously ill patient.
AVAILABLE AGENTS AND
TREATMENT GUIDELINES
Since the discovery and development of antimi-
crobial agents in the 20th century, many novel
agents have become available, including penicil-
lins, carbapenems, b-lactam–b-lactamase inhibitor
combinations, extended-spectrum cephalospo-
rins, aminoglycosides, monobactams, oxazolidi-
nones, ﬂuoroquinolones, macrolides, and
tetracyclines [7,8].
Many of these drugs have provided extended-
spectrum anti-Gram-positive and anti-Gram-neg-
ative activity, but despite the availability of these
agents, resistance continues to disseminate among
common pathogens (e.g. Staphylococcus aureus),
while pathogens with new types of resistance
emerge and spread (e.g. CTX-M-producing Esc-
herichia coli and carbapenemase-producing Klebsi-
ella pneumoniae strains).
Because prevalence patterns of resistant organ-
isms vary widely and change continually, regio-
nal, national and local resistance must be
considered in the selection of appropriate anti-
bacterials to combat speciﬁc pathogens [3,4].
Accordingly, the appropriate use of both older
and newer agents is recommended through treat-
ment guidelines that address antibacterial use by
geographical region and type of infection. Guide-
lines for antibacterial use are most effective when
they are evidence-based and focus on practical
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recommendations that remain up to date through
ongoing monitoring of published clinical studies.
They should also focus on the level of risk for the
individual patient, which typically is different for
healthcare-associated and community-acquired
infections.
In the USA, the IDSA and the Surgical Infection
Society (SIS) regularly update guidelines address-
ing the diagnosis and management of skin and
soft tissue infections [8] and intra-abdominal
infections [7,9]. Tables 1 and 2 summarize the
suggested available antibacterials for initial treat-
ment of the most common of these infections as
determined by the IDSA. Additionally, current
SIS guidelines recommend ampicillin–sulbactam,
cefotetan, cefoxitin, ertapenem, imipenem–cilast-
atin, meropenem, piperacillin–tazobactam and
ticarcillin–clavulanic acid as single agents. For
combination therapy, an aminoglycoside (amika-
cin, gentamicin, netilmicin, or tobramycin) plus
an anti-anaerobe agent (clindamycin or metroni-
dazole; the latter is preferred) can be considered,
as well as aztreonam plus clindamycin, ce-
furoxime plus metronidazole, ciproﬂoxacin plus
metronidazole, or a third ⁄ fourth-generation ceph-
alosporin (cefepime, cefotaxime, ceftazidime, cef-
tizoxime, or ceftriaxone) with an anti-anaerobe
drug for treatment of intra-abdominal infection.
In discussing the addition of a second agent,
emphasis is placed upon achieving coverage of
anaerobes. These guidelines highlight the in vitro
activity afforded by carbapenems against routine
isolates of Enterococcus spp. Although they do not
ﬁnd a justiﬁcation for routine coverage of entero-
cocci in community-acquired intra-abdominal
infections, the current guidelines indicate the
Table 1. Guideline summary for antibiotic selection for skin and soft tissue infections adapted from the Infectious
Diseases Society of America [8]
Antimicrobial therapy for skin and soft tissue infectiona
MSSA MRSA
Agent Comment Agent Comment
Nafcillin or oxacillin Parental drug of choice; inactive
against MRSA
Vancomycin For MSSA in penicillin-allergic
patients; parenteral drug of
choice for treatment of infections
caused by MRSA
Cefazolin For penicillin-allergic patients,
except those with immediate
hypersensitivity reactions
Linezolid Bacteriostatic; limited clinical
experience; no cross-resistance
with other antibiotic classes;
expensive; may eventually
replace other second-line agents
as a preferred agent for oral
therapy of MRSA infections
Clindamycin Bacteriostatic; potential for
cross-resistance and emergence
of resistance in erythromycin-
resistant strains; inducible
resistance in MRSA
Clindamycin Bacteriostatic; potential for
cross-resistance and emergence
of resistance in erythromycin-
resistant strains; inducible
resistance in MRSA
Dicloxacillin Oral agent of choice for
methicillin-susceptible strains
Daptomycin Bactericidal; do not use in patients
with lung involvement
Cephalexin For penicillin-allergic patients,
except those with immediate
hypersensitivity reactions
Doxycycline,
minocycline
Bacteriostatic; limited recent
clinical experience
Doxycycline,
minocycline
Bacteriostatic; limited recent
clinical experience
Trimethoprim–
sulphamethoxazole
Bactericidal; limited published
efﬁcacy data
Trimethoprim–
sulphamethoxazole
Bactericidal; efﬁcacy poorly
documented
MSSA, methicillin-sensitive Staphylococcus aureus; MRSA, methicillin-resistant S. aureus.
aAlso provides recommendations for treating impetigo caused by Streptococcus and Staphylococcus spp.; dicloxacillin, cephalexin, erythromycin (cautionary note that some
strains of S. aureus and Streptococcus pyogenes may be resistant), clindamycin, amoxycillin–clavulanate and mupirocin ointment are listed as recommended treatments.
Table 2. Guideline summary for antibiotic selection rec-
ommended for community-acquired intra-abdominal
infections adapted from the Infectious Diseases Society of
America [9]
Ampicillin–sulbactama
Ticarcillin–clavulanic acid
Piperacillin–tazobactamb
Ertapenem
Cefazolin or cefuroxime plus metronidazole
Ciproﬂoxacin and similar quinolones plus metronidazole
Aztreonam plus metronidazole
aLocal susceptibility proﬁles should be reviewed before
use.
bRecommended for serious infection.
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importance of such initial therapy for the higher-
risk patient with an infection of suspected health-
care-associated origin [7].
Tellado et al. [10] have published the Spanish
Guidelines under the auspices of the Sociedad
Espan˜ola de Quimioterapia and other Spanish
surgical and infectious disease societies. These
authors summarize appropriate initial treatment
of intra-abdominal infections in light of IDSA, SIS
and other published guidelines, including those
of the Societe´ Franc¸aise d’Anesthe´sie et de Re´an-
imation [11], and the Consejo Europeo. Table 3
summarizes the activity proﬁles of currently
available antibacterials published in the Spanish
Guidelines.
MECHANISMS OF ACTION AND
RESISTANCE
Antibacterial agents prevent bacterial growth by
disrupting the function of a wide variety of
molecular targets located within bacteria and at
the cell surface [12]. Fig. 1 summarizes the mech-
anisms of action of the most commonly used
antibacterials. The penicillins, cephalosporins and
carbapenems all target cell wall synthesis by
inhibiting the transpeptidases required for pepti-
doglycan formation and cross-linking in the cell
wall. Examples of drug target site modiﬁcations
occurring in drug-resistant bacteria include pen-
icillin-binding protein alterations that confer
resistance to the b-lactam antibiotics and DNA
gyrase mutations that alter the effectiveness of the
ﬂuoroquinolones. Enzymatic degradation of anti-
biotics is a mechanism that is usually associated
with Gram-negative bacteria, and in the case of
b-lactam resistance, it is due to b-lactamase
production.
The ﬂuoroquinolones block DNA synthesis by
inhibiting DNA gyrase and topoisomerase IV,
which are responsible for the DNA folding and
supercoiling required for replication. Glycopep-
tide antibiotics (e.g. vancomycin) form complexes
with the peptidoglycan that prevent binding of
the transpeptidases that are responsible for ter-
minal cross-linking. Metronidazole causes DNA
damage that ultimately leads to cell death. The
sulphonamides, trimethoprim–sulphamethox-
azole and iclaprim (discussed elsewhere in this
issue) block the metabolism of bacteria by inhib-
iting the enzymes needed for the synthesis of folic
acid.
Many antibiotics, including the aminoglyco-
sides, macrolides, oxazolidinones, streptogra-
mins, lincosamides, and tetracyclines, interact
with bacterial ribosomes at various sites to inhibit
protein synthesis. In particular, the tetracyclines
and glycylcyclines bind to the 30S subunit to
inhibit binding of aminoacyl-tRNA to the A site of
the ribosome and prevent the transfer of amino
acids to newly forming protein chains (Fig. 1).
Glycylcyclines are a new class of semisynthetic
Table 3. Activity proﬁles of anti-
microbial agents listed for empirical
therapy in the Spanish guidelines
[10]
Escherichia
colia
Bacteroides
fragilis
Enterococcus
faecalis
Staphylococcus
aureusb
Pseudomonas
aeruginosa
Amoxycillin–clavulanic acidc ++ +++ +++ +++ –
Piperacillin–tazobactam +++ +++ +++ +++ +++
Cephamycinsd +++ ++ – ++ –
Cefotaxime–ceftriaxone +++ – – +++ –
Cefepime +++ – – +++ ++
Carbapenemse +++ +++ ++f +++ +++g
Ciproﬂoxacin ++ – – + ++
Metronidazole – +++ – – –
Clindamycin – ++ – ++ –
Aminoglycosides +++ – + + +++h
Ampicillin + – +++ – –
Glycopeptides – – +++ +++i –
Linezolid – – +++ +++i –
Aztreonam +++ – – – ++
+, activity for approximately 50% of isolates; ++, activity for approximately 75% of isolates; +++, activity for more
than 90% of isolates.
aActivity against Klebsiella spp., Proteus spp., and Enterobacter spp.
bMethicillin-susceptible S. aureus only.
cThe activity of ampicillin–sulbactam is superior to that of amoxycillin–clavulanic acid.
dCephamycins: cefotaxime, cefmetazole, and cefminox.
eCarbapenems: imipenem, meropenem, and ertapenem.
fMeropenem and ertapenem both have little activity against Enterococcus sp.
gThe activity of imipenem in Spain is 86.2%, and ertapenem (MIC90 >16 mg ⁄L) is less active than imipenem.
hAmikacin and tobramycin.
iGlycopeptides: teicoplanin; vancomycin and linezolid are active against resistant strains of methicillin-resistant
S. aureus.
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tetracyclines developed with the intention of
circumventing both efﬂux- and target modiﬁca-
tion-mediated resistance to tetracyclines [12].
Bacteria that have developed tetracycline resis-
tance have commonly acquired the ability to
protect the bacterial target (the ribosome) or to
produce efﬂux pumps that extrude the drug
molecule from the cell; both mechanisms are
evaded by tigecycline, the ﬁrst glycylcycline, due
to a bulky substituent. Thus, the diverse resis-
tance mechanisms affecting the antimicrobial
agents described should not have an effect on
tigecycline, indicating that cross-resistance to this
new agent, due to these mechanisms, should not
be expected in otherwise multidrug-resistant bac-
teria.
SELECTION OF EMPIRICAL
ANTIMICROBIAL THERAPY
Several decisions are important in selecting initial
antimicrobial therapy, most importantly in sur-
mising what the likely infecting pathogen is
(based on the clinical presentation) and in choos-
ing the adequate regimen on the basis of knowl-
edge of the local antibiotic susceptibility of the
expected pathogen, as well as of the pharmaco-
kinetics of the chosen therapeutic agent. Other
ancillary factors can also impact on the overall
choice of antimicrobial therapy. These include
ease of drug administration [13], potential
adverse events, the complex dosing schedules
necessary with combination therapy, which can
carry an increased risk of drug interactions, the
need to monitor blood levels of some agents,
complicated dosing adjustments in selected pa-
tients with renal disease or hepatic dysfunction,
and treatment cost [6]. However, it is important to
understand that the most critical aspect of therapy
leading to a positive clinical outcome is early
treatment with an effective agent.
The role of monotherapy
The intuitive beneﬁt of monotherapy is that it
subjects bacteria to less exposure to antimicrobial
agents than combination therapy and thus might
lead to a slowing of resistance development.
Additional beneﬁts include less complexity of
drug administration and typically a lower overall
therapeutic cost. Clinical evidence supports the
hypothesis that certain antibacterials used as
monotherapy are as efﬁcacious as regimens that
involve the addition of one or more drugs. As
noted earlier, a meta-analysis by Bliziotis et al. [6],
incorporating eight studies published between
1983 and 1995, revealed that b-lactam monother-
apy was not associated with a greater emergence
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Fig. 1. Schematic diagram of various mechanisms of bacterial resistance. Adapted from reference [12].
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of resistance than was aminoglycoside–b-lactam
combination therapy (OR 0.90; 95% CI 0.56–
1.47). Importantly, b-lactam monotherapy was
associated with fewer superinfections (OR 0.62;
95% CI 0.42–0.93) and treatment failures
(OR 0.62; 95% CI 0.38–1.01). Also, all-cause mor-
tality during treatment (OR 0.70; 95% CI 0.40–
1.25) and mortality due to infection (OR 0.74;
95% CI 0.46–1.21) did not differ signiﬁcantly
between the two regimens.
Another study, by Cometta et al., found that the
addition of vancomycin therapy did not improve
the time to defervescence or lower mortality in
piperacillin–tazobactam-treated, persistently feb-
rile neutropenic patients with cancer (Fig. 2) [14].
The outcome of this prospective, randomized,
double-blind, multicentre trial (34 centres of the
EORTC-IATG), which included adults and chil-
dren (aged ‡2 years) in Europe, the Middle East
and North America, and had as a primary
objective the assessment of whether or not the
addition of a glycopeptide would reduce the time
to defervescence in neutropenic patients who had
persistent fever, was that there was no beneﬁt
over monotherapy.
TIGECYCLINE: A NEW
MONOTHERAPY OPTION
Tigecycline (Wyeth, formerly GAR-936) is the ﬁrst
glycylcycline antibacterial agent to be available
for clinical use. It was approved for use by the US
Food and Drug Administration (FDA) in June
2005, and is the ﬁrst new tetracycline analogue
since the introduction of minocycline over
30 years ago [15–17]. The chemical structures of
tetracycline, minocycline and tigecycline are
shown in Fig. 3. As a glycylamido derivative of
minocycline [16,17], tigecycline binds to the 30S
ribosomal subunit [16–18]. Tigecycline possesses
an expanded spectrum of in vitro activity [17],
and overcomes tetracycline resistance by retain-
ing the ability to bind to bacterial ribosomes that
are protected by the Tet(M) protein, a mechanism
that compromises all available tetracyclines [16–
18]. Tigecycline also evades the Tet(A–E) efﬂux
pumps, which account for most of the acquired
resistance to tetracycline and minocycline in
Enterobacteriaceae and Acinetobacter spp., as well
as the Tet(K) pumps, which occur widely in
staphylococci and confer resistance to tetracy-
cline, although not to minocycline or doxycycline
[16]. It has been shown that overproduction of the
AcrAB multidrug efﬂux pump is probably a key
factor leading to decreased tigecycline suscepti-
bility when found in E. coli [19].
Summary of in vitro activity
The results of the Tigecycline Evaluation and
Surveillance Trial (TEST) in vitro study published
by Hoban et al. [20] demonstrated that tigecycline
is highly active against the majority of commu-
nity- and healthcare-associated Gram-positive
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Fig. 2. Comparison of time to
defervescence in patients with per-
sistent fever 48–60 h after initiation
of empirical piperacillin–tazobactam
monotherapy randomized to receive
in addition either vancomycin or
placebo. Median days (95% CI).
p >0.5. Adapted from reference [14].
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bacterial isolates. Table 4 presents the in vitro
activities of tigecycline and other commonly
prescribed antimicrobials against over 2000
Gram-positive isolates from 40 study centres in
11 countries, as of December 2004. This study
included important antibiotic-resistant strains
such as methicillin-resistant S. aureus (MRSA)
[20]. The global in vitro susceptibility data
showed that tigecycline is highly active against
the majority of Gram-positive isolates tested,
including MRSA. The clinical trial data published
by Florescu et al. demonstrated that the in vitro
activity was matched by the clinical treatment
results [21]. Similarly, although the numbers of
isolates were smaller, 100% of the vancomycin-
resistant enterococcal isolates tested were suscep-
tible to tigecycline. The TEST study also showed
that tigecycline is highly active against Enterobac-
teriaceae, with activity similar to that of imipenem,
and superior to that of numerous comparator
agents, including ceftazidime and piperacillin–
tazobactam (Table 5). In other studies, tigecycline
has demonstrated potent activity against Entero-
bacteriaceae, including extended-spectrum b-lac-
tamase (ESBL)-, CTX-M-9-, SHV-producing E. coli
[22,23] and non-ESBL-producing K. pneumoniae
[24].
Of note, Morosini et al. reported the in vitro
activity of nine antibacterials against organisms
with ESBL phenotypes characteristically associ-
ated with cross-resistance to other drug classes,
and tigecycline and imipenem demonstrated sim-
ilar activity against 285 ESBL-producing isolates
from Spain (community and healthcare-associ-
ated Enterobacteriacea), exhibiting the lowest
MIC90 values (1.0 mg ⁄L for tigecycline; 0.5 g ⁄L
for imipenem) of all agents tested (Table 6) [22].
The most commonly observed ESBLs were CTX-
M-type enzymes (in >58% of both nosocomial
and community isolates), and these were typically
associated with cross-resistance to other antimi-
crobials, including aminoglycosides, ﬂuoroqui-
nolones, sulphonamides, and trimethoprim [22].
An additional study conducted in Spain by
Sorlo´zano et al., which used the breakpoint for
tigecycline established by the FDA in 2005 for
Enterobacteriaceae (MIC £2 mg ⁄L), demonstrated
that 100% of the ESBL-producing E. coli isolates
were susceptible to tigecycline, and all of the
isolates tested were inhibited by a concentration
of £0.75 mg ⁄L, regardless of the type of ESBL
produced [23]. Although the long-term success of
the strategy of using a new agent (e.g. tigecycline)
for monotherapy will depend on clinical
response, the initial blinded, randomized clinical
trials showing the efﬁcacy of tigecycline are
encouraging [25,26].
Antibacterial resistance is often thought to
begin in intensive-care units in patients with
infection, and resistance among speciﬁc Gram-
Tetracycline 
Minocycline
Tigecycline 
9-tert-butyl-glycylamido 
side chain added to the D 
ring at the 9th position 
Fig. 3. Chemical structures of tetra-
cycline, minocycline, and tigecycline.
Adapted from references [16–18].
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negative non-fermenters is viewed as a particular
threat in this setting. Tigecycline is active (in vitro)
against many non-fermenting Gram-negative bac-
teria (e.g. Acinetobacter spp. and Stenotrophomonas
maltophilia), with the important exception of
Pseudomonas aeruginosa. The recent publication of
a systematic review and an open-label trial
suggests that the in vitro activity of tigecycline
translates into effective clinical response when
this new agent is used in the therapy of serious
infection due to these difﬁcult-to-treat pathogens
[27,28]. In a large in vitro trial, Sader et al. [29]
tested the susceptibility of 9093 non-fermenting
Gram-negative isolates from bloodstream
(68.5%), respiratory tract (13.6%), skin ⁄ soft tissue
(5.5%) and urinary tract (2.0%) infections in
intensive-care unit patients between 2000 and
2004. Tigecycline and trimethoprim–sulphameth-
oxazole were the most active against Acinetobacter
spp. and Stenotrophomonas maltophilia among all
the antibacterials tested (MIC90 £2 mg ⁄L). As
expected, tigecycline proved to be ineffective
against P. aeruginosa strains (MIC90 16 mg ⁄L),
although 93.3% of 171 Acinetobacter baumannii
isolates tested were susceptible to tigecycline
(susceptibility breakpoint of £2 mg ⁄L) [29]. Also
reported was the alarming ﬁnding of a high level
of vancomycin resistance among enterococci,
ESBL-mediated b-lactam resistance, ﬂuoroquino-
lone resistance among Enterobacteriaceae, and
carbapenem resistance among P. aeruginosa and
Acinetobacter spp. Tigecycline showed consistently
good activity against these organisms with the
indicated resistance phenotypes, except against
P. aeruginosa [24].
Waites et al. reported additional data from the
TEST program in 2006 [24] that demonstrate the
efﬁcacy of tigecycline against A. baumannii as
well as ESBL-producing and non-producing
K. pneumoniae. Susceptibility was determined
according to the testing methods and interpretive
criteria of the CLSI. For tigecycline, the FDA-
approved criteria were applied to those organ-
isms that are listed in the package insert. Among
a total of 1460 strains of K. pneumoniae screened,
126 (8.6%) were conﬁrmed ESBL producers.
Tigecycline activity was unaffected by ESBL
production, and was the only compound to
which more than 90% of ESBL-producing isolates
were susceptible. Livermore [16] points out that
many carbapenemase-producing A. baumannii
isolates are resistant to all available agents except
the polymyxins, which, in addition to their
in vitro antibacterial activity, have the drawbacks
of toxicity and poor penetration into respiratory
secretions. Because tigecycline is active against
Table 4. Tigecycline in vitro activity: Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA)
and vancomycin-resistant enterococci (VRE)
Percentage susceptible
S. aureusa,b
(n = 489)
MRSAb,c
(n = 348)
Streptococcus
agalactiaeb
(n = 328)
Enterococcus
faecium
(non-VRE)
(n = 68)
Enterococcus
faecium
(VRE)
(n = 77)
Enterococcus
faecalisa,b
(non-VRE)
(n = 333)
Enterococcus
faecalis
(VRE)
(n = 11)
Tigecyclinec 99.8 98.9 100 95.6 100 99.1 100
Ampicillin 16.2 – 99.4 35.3 – 98.5 –
Ceftriaxone 89.2 – 98.8 NR – NR
Levoﬂoxacin 82.2 17.0 97.0 26.5 0 58.9 9.1
Linezolid 100 100 100 98.2 99.1 98.2 100
Minocycline 99.2 96.8 NR 72.1 62.3 38.1 36.4
Vancomycin 100 99.7 100 NR – NR –
Adapted from reference [20].
NR, not reported.
aClinical efﬁcacy has been demonstrated for susceptible strains in complicated intra-abdominal infections.
bClinical efﬁcacy has been demonstrated for susceptible strains in complicated skin and soft tissue infections.
cBreakpoint for susceptibility is £0.5 mg ⁄L for S. aureus, and £0.25 for Streptococcus spp. (other than Streptococcus pneumoniae) and Enterococcus sp.
Table 5. Global in vitro activity of antimicrobial agents
against 3201 clinical isolates of Enterobacteriaceae
Antimicrobial MIC90 (mg ⁄L) % susceptible
Tigecycline 1 96.7
Amikacin 4 99.0
Amoxycillin–clavulanate >32 51.0
Ampicillin >32 17.0
Cefepime 2 95.9
Ceftazidime 32 86.5
Ceftriaxone 16 88.8
Imipenem 1 98.7
Levoﬂoxacin 8 87.2
Minocycline 8 86.0
Piperacillin–tazobactam 16 90.7
Adapted from reference [20].
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most carbapenemase-producing A. baumannii
strains (MICs £2 mg ⁄L), it may provide a useful
alternative or adjunct to polymyxins, with a
comparable potency [29].
Pharmacokinetics and dosing
In three phase 1 studies of single and multiple
doses ranging from 12.5 to 300 mg in healthy
subjects, tigecycline exhibited linear pharmacoki-
netics at steady state, a large apparent volume of
distribution (7–10 L ⁄kg), and a long elimination
half-life (t1 ⁄ 2), ranging from 37 to 67 h [30].
Systemic clearance ranged from 0.2 to 0.3 L ⁄h ⁄ kg.
Food intake afforded a higher tolerability of a
single dose (between 100 and 200 mg), but the
duration of infusion did not affect tolerability.
Nausea and vomiting were the most common side
effects observed in these studies, and appeared to
be dose-related.
These ﬁndings conﬁrm those of earlier tigecy-
cline pharmacokinetic studies, which have shown
that multiple doses of a 30-min infusion of 50 mg
of tigecycline every 12 h produce a linear phar-
macokinetic course, with a maximum plasma
concentration (Cmax) of 0.87 mg ⁄L, whereas a
single 100-mg dose of tigecycline produces a
terminal t1 ⁄ 2 of 27 h. The minimum serum con-
centration (Cmin) observed with tigecycline is
0.13 mg ⁄L, and the area under the serum con-
centration–time curve from 0 to 24 h (AUC0–24 h)
is 4.7 mg h ⁄L. The average steady-state apparent
volume of distribution (Vss) is 639 L, which
indicates that tigecycline has extensive distribu-
tion beyond the plasma volume, with deposition
into human tissues [31–33]. Tigecycline skin
tissue penetration has been demonstrated in a
study by Sun et al.; they used the ratio between
the tigecycline area under the blister ﬂuid con-
centration–time curve (AUC0–12 h) in experimen-
tally induced blisters and the serum equivalent
after a total of seven 50-mg intravenous doses in
healthy subjects, and found a mean rate of
tigecycline penetration into the blister ﬂuid of
74% [34].
A single-dose (100 mg, intravenous) study by
Rodvold et al. in patients undergoing elective
surgery or medical procedures yielding tissue
for drug extraction found that the concentration
of tigecycline exceeded that found in serum
23-fold in gall bladder tissue, two-fold in lung
tissue, and 2.6-fold in colon tissue [35]. Another
recent study, by Ji et al., demonstrates the impor-
tance of the assay technique, as it was shown that
Table 6. In vitro activity of tigecycline against 285 ex-
tended-spectrum b-lactamase-producing Enterobacteriaceae
Antimicrobial
MIC (mg ⁄L)
%
susceptibleRange 50% 90% Mode
Piperacillin–tazobactam £0.5 ⁄ 4–‡128 ⁄ 4 16 ⁄ 4 16 ⁄ 4 16 ⁄ 4 93
Cefotaxime 0.5–512 256 256 256 0
Ceftazidime 0.12–256 4 256 256 0
Cefepime 1–64 64 64 64 0
Aztreonam 0.5–256 64 128 128 0
Imipenem £0.06–2 0.5 0.5 0.5 100
Ciproﬂoxacin £0.12–8 1 8 £0.12 64.9
Minocycline 0.5–128 4 32 2 69.5
Tigecycline 0.12–4 0.5 1 0.5 97.5
Adapted from reference [22].
Complicated skin and Soft-tissue
infection (cSSTI)
Complicated intra-abdominal
infection (cIAI) 
Tigecycline Vancomycinplus aztreonam Imipenem-cilastatin
87 8789
0
20
40
60
80
100
n = 422 n = 411 n = 685 n = 679
Cure
rate
(%)
87
Fig. 4. Clinical cure rates in compli-
cated skin and soft tissue infection
(cSSTI) and complicated intra-
abdominal infection (cIAI) phase 3
studies of tigecycline and compara-
tors. Adapted from references
[25,26].
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tigecycline concentration in bone exceeded that in
serum several-fold when careful drug extraction
was performed [36].
The standard dosage of tigecycline is 100 mg
administered intravenously, followed by 50 mg
every 12 h; importantly, no dosing adjustments
are needed in cases of renal impairment or
mild ⁄moderate hepatic disease [33]. Also, the
pharmacokinetic parameters of tigecycline do not
differ signiﬁcantly between sexes, or across age
groups (healthy subjects aged 18–50, 55–75 and
>75 years); therefore, no dosage adjustment is
necessary according to age or sex [37], thus
simplifying its use.
ITT: All Randomised subjects 
n = 1129 
Did not meet severity criteria 
n = 59 
Tigecycline = 128, V/A = 31 
Clinical mITT
n = 1057
Tigecycline = 538, V/A = 519
Did not meet evaluability criteria 
n = 224 
Tigecycline =116, V/A = 108 
No baseline pathogen 
n = 288 
Tigecycline = 143, V/A = 145 
Clinically evaluable 
n = 833 
Tigecycline = 422, V/A = 411 
Microbiologic mITT  
n = 769 
Tigecycline = 395, V/A = 374  
No baseline and/or susceptible pathogen 
n = 293 
Tigecycline = 143, V/A = 150 
Microbiologically evaluable 
n = 540 
Tigecycline = 279, V/A =261 
Clinical mITT 
n = 1057 
Tigecycline = 538, V/A = 519 
mITT:  At least 1 dose of study drug 
n = 1116 
Tigecycline = 566, V/A = 550 
No study drug received 
n = 13 
Tigecycline = 4, V/A = 9 
Did not pass screening 
n = 24 
Studies 3074A1-300-US/CA and 305-WW 
Total subjects screened 
n = 1153 
Fig. 5. Schema of patients in studies of tigecycline vs. vancomycin–aztreonam (V ⁄A) in the treatment of skin and skin
structure infections. ITT, intent-to-treat; mITT, modiﬁed intent-to-treat. Adapted from reference [26].
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Tigecycline is not extensively metabolized, and
is eliminated primarily by the biliary–faecal route.
In healthy male volunteers receiving [14C]tigecy-
cline, tigecycline was the primary 14C-labelled
material recovered in urine and faeces, but a
glucuronide, an N-acetyl metabolite and a tigecy-
cline epimer (each at no more than 10% of the
administered dose) were also present. The recov-
ery of total radioactivity in faeces and urine
following administration of [14C]tigecycline indi-
cates that 59% of the dose is eliminated by biliary–
faecal excretion, and 33% is excreted in the urine,
with approximately 22% of the total dose being
excreted as unchanged tigecycline in urine [38].
In vitro studies in human liver microsomes
indicate that tigecycline is not metabolized by,
and does not inhibit or induce, cytochrome enzy-
mes, including cytochrome P450 isoforms 1A2,
2C8, 2C9, 2C19, 2D6, and 3A4. Thus, it has a low
potential for interactions with drugs that inhibit or
induce the activity of these cytochrome P450 iso-
forms [33]. The only cautionary note regarding
drug–drug interactions is based on phase 1 safety
data that show increases inwarfarinCmax andAUC
when this drug is administered with tigecycline.
However, warfarin did not affect the pharmacoki-
netic proﬁle of tigecycline [33].
Clinical implications of pharmacodynamic
measures
One pharmacodynamic variable affecting the
broad-spectrum efﬁcacy of an antibacterial agent
is the measurable ratio between pharmacokinetic
parameters and bacterial susceptibility. Ambrose
et al. recently reported that the AUC0–24 ⁄MIC
ratio is the appropriate clinically derived phar-
macokinetic–pharmacodynamic target for tigecy-
cline (in contrast to time above the MIC, which is
more applicable to b-lactams), citing a clinically
derived exposure–response AUC0–24 ⁄MIC ratio of
17.9 for tigecycline [39]. This pharmacodynamic
measure was validated in a pulmonary pharma-
cokinetic study by Conte et al. [40], which dem-
onstrated therapeutically favourable Cmax ⁄MIC90
and AUC ⁄MIC90 ratios for tigecycline activity
against Streptococcus pneumoniae, Chlamydia pneu-
moniae, Mycoplasma pneumoniae, Moraxella catarrh-
alis and Haemophilus inﬂuenzae. Time above the
MIC90 was 100% for all ﬁve of these respiratory
pathogens. The tigecycline AUC0–12 h (134 mg
h ⁄L) in alveolar cells was approximately 78-fold
higher than the AUC0–12 h in serum, and the
AUC0–12 h (2.28 mg h ⁄L) in epithelial lining
ﬂuid was approximately 32% higher than the
AUC0–12 h in serum.
Clinical trial data for complicated skin and soft
tissue infections and for complicated
intra-abdominal infections
In clinical studies, tigecycline has a demonstrated
efﬁcacy proﬁle in the treatment of both compli-
cated skin and soft tissue infections (cSSTIs) and
complicated intra-abdominal infections (cIAIs)
[21,25,26,28]. Tigecycline has been evaluated in
four large phase 3, double-blind, randomized,
multicentre, active-comparator clinical studies in
hospitalized patients with cSSTI or cIAI, in which
it was not inferior at the 15% level (cure vs.
failure) at test-of-cure assessments in either the
cSSTI studies (p <0.0001) or the cIAI studies
(p <0.0001). Fig. 4 summarizes the clinical cure
rates for each of the two pooled study pairs. In
the cSSTI studies used for drug approval, similar
clinical cure rates were obtained with tigecycline
and vancomycin–aztreonam (87% vs. 89%); rates
were also similar for patients with monomicrobial
MRSAMSSA Enterococcus
faecalis
Streptococcus
spp.a
Bacteroides
fragilis
Escherichia
coli
Tigecycline Vancomycin plus aztreonam 
89 91
78 76
88
92 91 89 90 
83
100 
80
134 120 32 33 16 24 56 47 29 30 8 5
0
40
60
80
100
20
Cure
rate
(%)
Fig. 6. Cure rates by pathogen in
the microbiologically evaluable
population of the complicated skin
and skin structure studies (tigecy-
cline vs. vancomycin–aztreonam).
MSSA, methicillin-susceptible Staph-
ylococcus aureus; MRSA, methicillin-
resistant S. aureus. aStreptococcus
spp. includes S. anginosus, S. inter-
medius, and S. constellatus. Adapted
from reference [26].
40 Clinical Microbiology and Infection, Volume 14, Supplement 6, December 2008
 2008 The Author
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 6), 30–45
and polymicrobial infections [26]. Fig. 5 pre-
sents the study design and disposition for this
pooled analysis. Tigecycline monotherapy was
shown to be as effective as vancomycin–aztreo-
nam for treating cSSTIs. Cure rates with respect
to pathogens were similar for the two treatment
groups (e.g. 78% vs. 76% for MRSA), and non-
inferiority was demonstrated in all treatment
subsets. Fig. 6 summarizes the results from the
microbiologically evaluable populations in these
studies [26].
In the cIAI studies used for drug approval,
tigecycline gave clinical cure rates similar to
imipenem (each 86%), and rates were also similar
ITT: All Randomised subjects
n = 1658
Did not meet minimal disease criteria
 n = 41
Tigecycline = 16, I/C = 25
Clinical mITT
n = 1601
Tigecycline = 801, I/C = 100
Did not meet evaluability criteria
n = 219
Tigecycline =116, I/C = 103
No baseline isolate
n = 339
Tigecycline = 170, I/C = 169
Clinically evaluable
n = 1382
Tigecycline = 685, I/C = 697
Microbiologic mITT
n = 1262
Tigecycline = 631, I/C = 631
No baseline or susceptible isolate
n = 357
Tigecycline = 173, I/C = 184
Microbiologically evaluable
n = 1025
Tigecycline = 512, I/C =513
Clinical mITT
n = 1601
Tigecycline = 801, I/C = 100
mITT:  At least 1 dose of study drug
n  = 1642
Tigecycline = 817, I/C = 825
No study drug received
n = 16
Tigecycline = 9, I/C = 7
Did not pass screening
n = 101
Studies 3074A1-301 and 306
Total subjects screened
n = 1759
Fig. 7. Schema of patients in studies of tigecycline vs. imipenem–cilastatin (I ⁄C) in the treatment of complicated intra-
abdominal infections. ITT, intent-to-treat; mITT, modiﬁed intent-to-treat. Adapted from reference [25].
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for patients with monomicrobial and polymicro-
bial infections. Fig. 7 presents the study design
and disposition for this pooled analysis. Tigecy-
cline monotherapy was shown to be as effective as
imipenem–cilastatin for treating cIAIs [25]. Cure
rates according to diagnosis were also similar
for the two treatment groups (e.g. 88% vs.
89% for complicated appendicitis), and non-
inferiority was demonstrated in all treatment
subsets. Fig. 8 summarizes the results from the
microbiologically evaluable populations in these
studies.
Summary of tigecycline safety data in phase 3
cSSTI and cIAI studies
On the basis of 1415 tigecycline-treated and 1382
comparator-treated patients, nausea, vomiting
and hyperbilirubinaemia were reported as ad-
verse events signiﬁcantly more often with tigecy-
cline than with the comparator agents: 29.5% vs.
15.8%, 19.7% vs. 10.8%, and 2.3% vs. 0.9%,
respectively [32,33]. Most cases of nausea and
vomiting were mild to moderate, and treatment
discontinuation rates due to adverse events were
similar between tigecycline and comparator treat-
ment groups for cSSTIs (20 (3.5%) for tigecycline;
29 (5.3%) for vancomycin–aztreonam (p 0.188))
[26] and for cIAIs (21 (2.6%) for tigecycline; 12
(1.5%) for imipenem–cilastatin (p 0.116)) [25].
Table 7 summarizes commonly reported adverse
events at the test-of-cure visit in these tigecycline
phase 3 studies.
BENEFITS OF SINGLE VS. MULTIPLE
AGENTS
As the provision of healthcare becomes ever more
complex, the administration of a single agent
becomes more attractive, even if it is a new,
potent antibiotic that historically might have been
reserved in order to prevent the development of
resistance to the new compound. At the current
stage of emerging resistance, it is important to
reconsider entrenched habits and assess whether
simpliﬁed forms of antimicrobial stewardship
will improve the treatment of infectious diseases.
An additional argument in favour of monother-
apy, considering also that reduced antibiotic use
should result in reduced antimicrobial resistance,
is the lower risk of toxicity and therapy-related
adverse events when only a single agent is
prescribed.
CONCLUSION
Resistance to virtually all classes of antimicrobial
agents is increasing, which highlights the fact that
past practices during the last half-century and
beyond have not been sufﬁcient to prevent the
development and spread of resistant pathogens.
The inescapable conclusion from history is that
0
40
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100
20
88 89 97 95
75 73
78 78 
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92 92 89 90 
67 
60
n = 263 262 69 74 51 45 51 40 32 42 25 25 18 20 3 5
Imipenem-Cilastatin Tigecycline 
Complicated 
appendicitis Complicated 
cholecystitis Intra-abdominal 
abscess Perforated 
intestine 
Complicated 
diverticulitis
Gastric/Duodenal
perforations Peritonitis 
Other 
Cure
rate
(%)
Fig. 8. Cure rates by diagnosis in the microbiologically evaluable population of the complicated intra-abdominal infection
studies (tigecycline vs. imipenem–cilastatin) Adapted from reference [25].
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emerging resistance is intrinsic to antibacterial
therapy itself, and that treatment, in the long
term, leads to resistance in the very pathogens
that it is intended to eradicate [17]. New strategies
to slow the emergence of resistance require a
paradigm shift in our use of antimicrobial agents.
Increasing worldwide resistance in key pathogens
(MRSA, enterococci, and enteric Gram-negative
organisms) requires a reassessment of how we
make the initial choice of treatment for likely
infection, whenever the offending pathogen will
remain unknown for several days. For example,
rising MRSA infection rates will lead to an
increased use of combination therapy unless
monotherapy with a suitable agent is adopted.
Data from many published studies argue that, as
a general rule, combination therapy offers no
advantage over monotherapy with an antimicro-
bial agent with a suitable spectrum of activity
[5,13,41–43]. Although exclusive use of monother-
apy is a clinically unrealistic objective, expanded
prescription of a single agent, wherever it is likely
to provide effective treatment, can lower the
pressure for further development of resistant
pathogens, and help to maintain the therapeutic
foothold against an ever-worsening global prob-
lem concerning both community and healthcare-
associated resistant bacterial infections.
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